溴新斯的明(Neostigmine Bromide) - 药物靶点：ACHE_在研适应症：慢性胃炎，功能性便秘，排尿困难_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Neostigmine bromide (JAN/USP/INN)、Prostigmin

+ [2]

靶点

ACHE

作用方式

抑制剂、拮抗剂

作用机制

AChE抑制剂(乙酰胆碱酯酶抑制剂)、肌松拮抗剂

治疗领域

肿瘤免疫系统疾病神经系统疾病+ [2]

在研适应症

慢性胃炎功能性便秘排尿困难+ [1]

非在研适应症-

原研机构-

在研机构

Kyowa Pharmaceutical Industry Co., Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (1956-04-14),

慢性胃炎功能性便秘排尿困难+ [1]

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C12H19BrN2O2

InChIKeyLULNWZDBKTWDGK-UHFFFAOYSA-M

CAS号114-80-7

查看全部结构式(2)

关联

60

项与溴新斯的明相关的临床试验

NCT06685705

/ Not yet recruiting临床4期IIT

Comparative Study Between Intrathecal Magnesium Sulfate, Neostigmine and Fentanyl As Adjuvant for Bubivacaine in Postoperative Analgesia in Lower Abdominal Surgeries

Lower abdominal surgeries often result in severe pain, which in turn can cause rapid and shallow breathing, retention of secretions and poor patient compliance. Justifiably, apart from the fear for the surgery outcome, patients are concerned mainly with postoperative pain. If treated inadequately, acute pain can have serious consequences for patient health mainly with postoperative complications, prolonged recovery and increased length of hospital stay. Higher levels of postoperative pain and pain distress are associated with increased morbidity, poorer functional recovery, and reduced quality of life.
Aim of the study To compare the duration, quality of analgesia, and side effects between intrathecal Magnesium sulfate, neostigmine and fentanyl as adjuvant for bubivacaine as postoperative analgesia in lower abdominal surgeries

开始日期2024-12-01

申办/合作机构

Assiut University

CTRI/2023/07/055054

/ Not yet recruiting临床4期IIT

Effect of neostigmine on attenuation of proinflammatory cytokines secretion when given as an adjunctive therapy in septic shock: A Randomized controlled trial - NIL

开始日期2023-07-20

申办/合作机构

All India Institute of Medical Sciences

PACTR202304565008785

/ RecruitingN/AIIT

Intramuscular Neostigmine and Postoperative Urinary Retention After Spinal Anesthesia for knee Arthroscopy, a Prospective Randomized Controlled Study

开始日期2023-04-15

申办/合作机构

Mansoura University

100 项与溴新斯的明相关的临床结果

登录后查看更多信息

100 项与溴新斯的明相关的转化医学

登录后查看更多信息

100 项与溴新斯的明相关的专利（医药）

登录后查看更多信息

3,582

项与溴新斯的明相关的文献（医药）

2025-02-01·Chemical Engineering Journal

Novel colorimetric-fluorescent dual-mode biosensing platform for detecting acetylcholinesterase and screening acetylcholinesterase inhibitors based on trimetallic nanozymes

作者: Sun, Hongmei ; Liu, Mingxing ; Zheng, Meie ; Ma, Fei ; Zhu, Hongda ; Guo, Huiling ; Song, Zichen

Acetylcholinesterase (AChE) is an essential biomarker for neurodegenerative diseases.A precise, sensitive, and stable colorimetric-fluorescence dual-mode biosensing platform based on trimetallic nanozymes for detecting AChE and screening for AChE inhibitors was established in our work.Two-dimensional porous trimetallic carbon nitride-based nanomaterials (ZIF-8-Fe-Cu/BC/P-GCN) were successfully designed and prepared from urea, lotus seed shells, and ZIF-8.The sp. surface area of the nanomaterials was observed to be as high as 93.69 m²/g, and the increased number of defects promoted electron conduction.First-principles d. functional theory calculations and steady-state kinetic anal. were applied to investigate the electronic structures, adsorption energy mechanism, and oxidase-like properties of the trimetallic nanozymes.A dual-mode biosensing platform for detecting AChE, which displays a linear range of 1 ∼ 100 μU/mL and detection limits of 0.39 μU/mL (colorimetric), and, for fluorescence detection, displays a linear range of 20 ∼ 100 μU/mL with detection limits of 0.06 μU/mL, was developed.The spiking recoveries for AChE in human serum samples ranged from 98.0 % to 100.6 % (fluorescence) and 98.8 % to 101.2 % (colorimetric), mirroring the results obtained via Ellman′s method.Moreover, when AChE inhibitors such as rivastigmine tartrate, tacrine, and neostigmine bromide were used as examples, the IC₅₀ values were found to be 1.521, 6.348, and 9.182 nM, resp., for the colorimetric method and 1.468, 5.705, and 9.264 nM, resp., for the fluorescence method.The results of the two modes were cross-verified.The dual-mode biosensing platform can thus be used for AChE detection and to screen for AChE inhibitors, and has potential for the anal. of other biomarkers.

2024-12-01·Chemical Engineering Journal

Enhancing the efficiency and stability of carbon-based perovskite solar cells through treatment of the CsPbI2Br surface with neostigmine bromide

作者: Liu, Fengli ; Gao, Lin ; Tu, Yongsheng ; Lan, Zhang ; Wu, Jihuai ; Du, Zhenbo ; Jiang, Dongbin ; Li, Ruoshui

Carbon-based all-inorganic perovskite solar cells (C-PSCs) are reknown for their inexpensive manufacturing process.However, the perovskite constituents in C-PSCs are susceptible to the formation of numerous structural defects and halide vacancies, which can induce substantial energy level misalignments between the light-absorbing layer and the carbon electrode.This discrepancy hinders the extraction and transfer of holes, thereby adversely affecting the overall efficiency of the device.In this study, we propose an interfacial post-treatment strategy aimed at reinforcing perovskite layers through the application of Neostigmine bromide (NMB) as a modifier.NMB effectively promoted the recrystallization of intrinsic phase segregation on the surface of CsPbI₂Br film and enhanced the crystal integrity of perovskite surface.Furthermore, bromine ions (Br^-) can occupy halide vacancies.Incorporating NMB at the interface significantly reduces the surface defect concentration of the perovskite layer and optimizes the energy level alignment with the carbon electrode.Exptl. results demonstrate that the optimized device exhibits remarkable stability and achieves an striking power conversion efficiency (PCE) of 14.15%.This research lays the foundation for the development of cost-effective, high-performance, and durable all-inorganic perovskite solar cells.

2024-12-01·Current Neurology and Neuroscience Reports

Pharmacological Prevention of Postoperative Delirium in Adults: A Review of Recent Literature

Review

作者: White, Nathan C ; Cowart, Christopher R ; Cios, Theodore J

PURPOSE OF REVIEWPostoperative delirium (POD) is a common complication that has important implications for surgical patients, often leading to both short- and long-term cognitive deficits, worse outcomes, and increased healthcare costs. Given these implications, there may be a benefit in reducing the incidence of POD. Pharmacologic interventions may have the potential to reduce the risk of a patient developing POD.RECENT FINDINGSRecently studied therapies include dexmedetomidine, propofol, haloperidol, ketamine, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, acetaminophen, melatonin/ramelteon, corticosteroids, midazolam, physostigmine, and neostigmine. In addition, the implementation of regional anesthesia and reduction of overall anesthetic depth have been examined. Of these therapies, dexmedetomidine has been studied the most and has the most supporting evidence for prevention of POD, but current studies lack clarity on optimal dosing and timing of dexmedetomidine administration. Acetaminophen, corticosteroids, and melatonin/ramelteon are other plausible medications that have potential for reducing POD incidence, but they all require further investigation. Reduction of anesthetic depth and regional anesthetics are options for anesthetic management that show promise but still lack enough supporting evidence in recent literature to receive a strong recommendation. Future research should focus on identifying optimal strategies for the implementation of the pharmacological options listed, including doses and timing of administration. Attention should be given to dexmedetomidine given its promise demonstrated by recent literature.

100 项与溴新斯的明相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00995	溴新斯的明	S01EB06 N07AA01	DBSALT001191

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
慢性胃炎	日本	Kyowa Pharmaceutical Industry Co., Ltd.	1956-04-14
功能性便秘	日本	Kyowa Pharmaceutical Industry Co., Ltd.	1956-04-14
排尿困难	日本	Kyowa Pharmaceutical Industry Co., Ltd.	1956-04-14
重症肌无力	日本	Kyowa Pharmaceutical Industry Co., Ltd.	1956-04-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02909439 (CTgov)	临床4期	神经肌肉阻滞逆转	80	Neostigmine (Neostigmine)	觸鬱遞夢範鏇鏇糧鏇製(選襯齋積繭願淵鏇蓋願) = 網壓獵鏇鏇鹹鬱願窪鏇築鏇憲蓋糧構網製網遞 (築壓遞顧襯製製壓鹹構, 選鹽選顧鹹壓鹹鑰鹽壓 ~ 構蓋範淵淵醖襯選願願) 更多	-	2020-05-22
				Sugammadex (Sugammadex)	觸鬱遞夢範鏇鏇糧鏇製(選襯齋積繭願淵鏇蓋願) = 鑰範範襯鬱築蓋鏇膚遞築鏇憲蓋糧構網製網遞 (築壓遞顧襯製製壓鹹構, 築夢醖簾鬱壓膚簾網窪 ~ 鬱齋餘齋壓築構顧淵憲) 更多
NCT03276026 (CTgov)	临床4期	术后恶心呕吐	68	Neostigmine (Control Group/Neostigmine)	艱廠淵範壓築襯網蓋蓋(鬱蓋鹹壓鏇構淵積鏇艱) = 淵簾積壓鬱築鬱淵鹽襯鏇範簾餘衊遞壓獵觸糧 (襯夢蓋糧窪襯範鬱衊構, 夢餘積範艱觸淵遞範簾 ~ 範艱鬱獵夢憲範糧範襯) 更多	-	2019-05-28
				Sugammadex (Study Group/Sugammadex)	艱廠淵範壓築襯網蓋蓋(鬱蓋鹹壓鏇構淵積鏇艱) = 願糧蓋憲糧願範願範艱鏇範簾餘衊遞壓獵觸糧 (襯夢蓋糧窪襯範鬱衊構, 膚夢壓繭齋構構淵網憲 ~ 衊製壓製築艱繭網衊壓) 更多
NCT01962298 (SUDIA, CTgov)	临床3期	呼吸系统疾病 \| 肌肉疲劳 \| 肌肉无力	75	placebo+Single rocuronium dose (Single Rocuronium Dose - Placebo)	憲鑰淵鑰選築製遞蓋選(築繭壓鬱遞憲壓鹽夢淵) = 構膚範鹹糧艱襯網憲製艱積醖選夢壓獵鬱廠築 (膚壓夢糧淵鬱衊構構製, 艱窪選襯選艱壓餘齋衊 ~ 範夢鏇壓積廠壓觸憲憲) 更多	-	2018-10-24
				sugammadex 2mg/kg+Single rocuronium dose (Single Rocuronium Dose - Sugammadex)	憲鑰淵鑰選築製遞蓋選(築繭壓鬱遞憲壓鹽夢淵) = 醖鹽窪蓋膚餘觸糧獵築艱積醖選夢壓獵鬱廠築 (膚壓夢糧淵鬱衊構構製, 鬱構壓積鹹齋糧製網餘 ~ 繭製製鏇壓簾蓋簾網製) 更多